Contemporary Approach to the Diagnosis and Classification of Myelodysplastic Neoplasms/SyndromesdRecommendations From the International Consortium for Myelodysplastic Neoplasms/Syndromes (MDS [icMDS])

被引：1

作者：

Aakash, Fnu ^{[1
,2
]}

Gisriel, Savanah D. ^{[3
,4
]}

Zeidan, Amer M. ^{[5
]}

Bennett, John M. ^{[6
]}

Bejar, Rafael ^{[7
]}

Bewersdorf, Jan Philipp ^{[8
]}

Borate, Uma M. ^{[9
]}

Boultwood, Jacqueline ^{[10
]}

Brunner, Andrew M. ^{[11
]}

Buckstein, Rena ^{[12
]}

Carraway, Hetty E. ^{[13
]}

Churpek, Jane E. ^{[14
]}

Daver, Naval G. ^{[15
]}

Dezern, Amy E. ^{[16
]}

Efficace, Fabio ^{[17
]}

Fenaux, Pierre ^{[18
]}

Figueroa, Maria E. ^{[19
]}

Garcia-Manero, Guillermo ^{[15
]}

Gore, Steven D. ^{[20
]}

Greenberg, Peter L. ^{[21
]}

Griffiths, Elizabeth A. ^{[22
]}

Halene, Stephanie ^{[5
]}

Hourigan, Christopher S. ^{[23
]}

Kim, Tae Kon ^{[24
]}

Kim, Nina ^{[25
]}

Komrokji, Rami S. ^{[26
]}

Kutchroo, Vijay K. ^{[27
]}

List, Alan F. ^{[28
]}

Little, Richard F. ^{[20
]}

Majeti, Ravindra ^{[21
]}

Nazha, Aziz ^{[29
]}

Nimer, Stephen D. ^{[30
]}

Odenike, Olatoyosi ^{[31
,32
]}

Padron, Eric ^{[26
]}

Patnaik, Mrinal M. ^{[33
]}

Platzbecker, Uwe ^{[34
]}

Porta, Matteo G. Della ^{[35
]}

Roboz, Gail J. ^{[36
,37
]}

Sallman, David A. ^{[26
]}

Santini, Valeria ^{[38
]}

Sanz, Guillermo ^{[39
,40
,41
]}

Savona, Michael R. ^{[24
]}

Sekeres, Mikkael A. ^{[30
]}

Stahl, Maximilian ^{[42
]}

Starczynowski, Daniel T. ^{[43
]}

Steensma, David P. ^{[44
]}

Taylor, Justin ^{[30
]}

Abdel-Wahab, Omar ^{[8
]}

Wei, Andrew H. ^{[45
]}

Xie, Zhuoer ^{[26
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA

[2] Univ Texas Med Branch, Dept Pathol, Galveston, TX USA

[3] Yale Univ, Sch Med, Dept Pathol, New Haven, CT USA

[4] Univ Wisconsin Madison, Dept Pathol & Lab Med, Madison, WI USA

[5] Yale Sch Med, Yale Canc Ctr, Dept Internal Med, Sect Hematol,Sch Med, New Haven, CT USA

[6] Univ Rochester, Med Ctr, James P Wilmot Canc Ctr, Div Hematopathol, Rochester, NY USA

[7] Univ Calif San Diego, Moores Canc Ctr, Div Hematol & Oncol, La Jolla, CA USA

[8] Mem Sloan Kettering Canc Ctr, Dept Med, Leukemia Serv, New York, NY USA

[9] Ohio State Univ, Div Hematol, Comprehens Canc Ctr, Columbus, OH USA

[10] Univ Oxford, Nuffield Div Clin Lab Sci, Radcliffe Dept Med, Oxford, England

[11] Brigham & Womens Hosp, Div Hematol, Boston, MA USA

[12] Sunnybrook Hlth Sci Ctr, Dept Med, Div Med Oncol Hematol, Toronto, ON, Canada

[13] Cleveland Clin, Leukemia Program, Taussig Canc Inst, Hematol & Med Oncol, Cleveland, OH USA

[14] Univ Wisconsin Madison, Carbone Canc Ctr, Div Haematol Oncol & Palliat Care, Madison, WI 53706 USA

[15] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX USA

[16] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA

[17] Italian Grp Adult Hematol Dis GIMEMA, Hlth Outcomes Res Unit, Rome, Italy

[18] Univ Paris Cite, Serv Hematol, Paris, France

[19] Univ Miami, Miller Sch Med, Dept Neurol, Miami, FL 33136 USA

[20] NCI, Canc Therapy Evaluat Program, Rockville, MD USA

[21] Stanford Univ, Stanford Canc Inst, Sch Med, Dept Med,Div Hematol, Stanford, CA USA

[22] Roswell Park Comprehens Canc Ctr, Buffalo, NY USA

[23] Virginia Tech, Fralin Biomed Res Inst, FBRI Canc Res Ctr, Washington, DC USA

[24] Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Dept Med, Nashville, TN USA

[25] NCI, NIH, Bethesda, MD USA

[26] H Lee Moffitt Canc Ctr & Res Inst, Malignant Hematol Program, Tampa, FL USA

[27] Brigham & Womens Hosp, Boston, MA USA

[28] New York Infirm, New York, NY USA

[29] Thomas Jefferson Univ, Sidney Kimmel Med Coll, Philadelphia, PA USA

[30] Univ Miami, Dept Med, Div Hematol, Div Hematol,Miller Sch Med, Miami, FL USA

[31] Univ Chicago, Sect Hematol Oncol, Leukemia Program, Chicago, IL 60637 USA

[32] Univ Chicago, Comprehens Canc Ctr, Chicago, IL USA

[33] Mayo Clin, Dept Internal Med, Div Hematol, Rochester, MN USA

[34] Univ Hosp Leipzig, Dept Hematol & Cellular Therapy, Leipzig, Germany

[35] Humanitas Univ, Dept Biomed Sci, Milan, Italy

[36] New York Acad Med, New York, NY USA

[37] New York Presbyterian Hosp, New York, NY USA

[38] Univ Florence, Dept Expt & Clin Med, Myelodysplast Syndromes Unit, Hematol,Azienda Osped Univ Careggi, Florence, Italy

[39] Hlth Res Inst La Fe, Valencia, Spain

[40] Hosp Univ & Politecn La Fe, Valencia, Spain

[41] ISCarlosIII, CIBERONC, Madrid, Spain

[42] Harvard Med Sch, Dana Farber Canc Inst, Dept Med Oncol, Div Leukemia, Boston, MA USA

[43] Cincinnati Childrens Hosp, Div Expt Hematol & Canc Biol, Cincinnati, OH USA

[44] David Steensma LLC, Cambridge, MA USA

[45] Royal Melbourne Hosp, Dept Haematol Lab, Walter & Eliza Hall Inst Med Res, Melbourne, Vic, Australia

[46] Massachusetts Gen Hosp Brigham, Dept Pathol, Boston, MA USA

来源：

MODERN PATHOLOGY | 2024年 / 37卷 / 12期

关键词：

icMDS; MDS; myelodysplastic neoplasms; myelodysplastic syndromes; classification; diagnosis; HEALTH-ORGANIZATION CLASSIFICATION; FLOW-CYTOMETRY; COPPER DEFICIENCY; 5TH EDITION; MUTATIONS; VALIDATION; RISK; ABNORMALITIES; EVOLUTION; LEUKEMIA;

D O I：

10.1016/j.modpat.2024.100615

中图分类号：

R36 [病理学];

学科分类号：

100104 ;

摘要：

Myelodysplastic neoplasms/syndromes (MDS) are a heterogeneous group of biologically distinct entities characterized by variable degrees of ineffective hematopoiesis. Recently, 2 classification systems (the 5th edition of the World Health Organization Classification of Haematolymphoid tTumours and the International Consensus Classification) further subcharacterized MDS into morphologically and genetically defined groups. Accurate diagnosis and subclassification of MDS require a multistep systemic approach. The International Consortium for MDS (icMDS) summarizes a contemporary, practical, and multimodal approach to MDS diagnosis and classification. (c) 2024 United States & Canadian Academy of Pathology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

引用

页数：13

共 50 条

[31] Evaluation of the Molecular International Prognostic Scoring System (IPSS-M) in Patients (Pts) with Myelodysplastic Syndromes/Neoplasms (MDS) with Missing Molecular Data
Kewan, Tariq
Bewersdorf, Jan Philipp
Blaha, Ondrej
Stahl, Maximilian
Al Ali, Najla H.
DeZern, Amy E.
Sekeres, Mikkael A.
Carraway, Hetty E.
Desai, Pinkal
Griffiths, Elizabeth A.
Stein, Eytan M.
Brunner, Andrew M.
Amaya, Maria L.
Zeidner, Joshua F.
Savona, Michael R.
Stempel, Jessica M.
Chandhok, Namrata Sonia
Logothetis, Constantine
Cochran, Hunter
Singh, Abhay
Roboz, Gail J.
Rolles, Benjamin
Wang, Eunice S.
Harris, Amyah C.
Shallis, Rory M.
Xie, Zhuoer
Padron, Eric
Sallman, David A.
Maciejewski, Jaroslaw P.
Della Porta, Matteo Giovanni
Komrokji, Rami S.
Zeidan, Amer M.
BLOOD, 2023, 142
[32] Pathway Analysis of Molecular Mutations Can Modify Morphologic, Cytogenetic and Prognostic Risk Stratification Schemes in Myelodysplastic Syndromes (MDS), Myelodysplastic Syndromes/Myeloproliferative Neoplasms (MDS/MPN), and Secondary Acute Myeloid Leukemia (AML)
Hasrouni, Edy
Visconte, Valeria
Tabarroki, Ali
Rogers, Heesun J.
Traina, Fabiola
Jankowska, Anna
Liu, Yang
Hamilton, Betty K.
Bupathi, Manoj
Makishima, Hideki
Jerez, Andres
Copelan, Edward A.
Advani, Anjali
McDevitt, Michael A.
Kalaycio, Matt
Saunthararajah, Yogen
Sekeres, Mikkael A.
Maciejewski, Jaroslaw P.
Tiu, Ramon V.
BLOOD, 2012, 120 (21)
[33] Myelodysplastic/Myeloproliferative Neoplasms, Unclassifiable (MDS/MPN, U): Natural History and Clinical Outcome By Therapeutic Approach
DiNardo, Courtney D.
Daver, Naval G.
Jain, Nitin
Pemmaraju, Naveen
Bueso-Ramos, Carlos E.
Yini, Cheng
Pierce, Sherry R.
Jabbour, Elias
Quintas-Cardama, Alfonso
Cortes, Jorge E.
Kantarjian, Hagop M.
Garcia-Manero, Guillermo
Verstovsek, Srdan
BLOOD, 2013, 122 (21)
[34] Inter-observer variance with the diagnosis of myelodysplastic syndromes (MDS) following the 2008 WHO classification
P. Font
J. Loscertales
C. Benavente
A. Bermejo
M. Callejas
L. Garcia-Alonso
A. Garcia-Marcilla
S. Gil
M. Lopez-Rubio
E. Martin
C. Muñoz
P. Ricard
C. Soto
P. Balsalobre
A. Villegas
Annals of Hematology, 2013, 92 : 19 - 24
[35] Inter-observer variance with the diagnosis of myelodysplastic syndromes (MDS) following the 2008 WHO classification
Font, P.
Loscertales, J.
Benavente, C.
Bermejo, A.
Callejas, M.
Garcia-Alonso, L.
Garcia-Marcilla, A.
Gil, S.
Lopez-Rubio, M.
Martin, E.
Munoz, C.
Ricard, P.
Soto, C.
Balsalobre, P.
Villegas, A.
ANNALS OF HEMATOLOGY, 2013, 92 (01) : 19 - 24
[36] Data-driven, harmonised classification system for myelodysplastic syndromes: a consensus paper from the International Consortium for Myelodysplastic Syndromes (vol 11, pg e862, 2024)
Locatelli, F.
Antmen, B.
Kang, H. J.
LANCET HAEMATOLOGY, 2024, 11 (12): : e886 - e886
[37] Application of array-based karyotyping as a complementary tool in the diagnosis of myelodysplastic syndromes and related myeloid neoplasms
Abaigar, M.
Lumbreras, E.
Sanchez-del-Real, J.
Diez-Campelo, M.
Cuello, R.
Alonso, J. M.
Recio, I.
Aguilar, C.
Hermosin, L.
Rodriguez, J. N.
Megido, M.
Sierra, M.
Martin-Nunez, G.
Gonzalez-Lopez, T. J.
Vargas, M.
Fuster, J. L.
Giraldo, P.
Robledo, C.
Benito, R.
Hernandez-Rivas, J. M.
LEUKEMIA RESEARCH, 2013, 37 : S46 - S46
[38] Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Differential Diagnosis in the WHO and ICC 2022 Era: A Focused Review
Fontana, Diletta
Elli, Elena M.
Pagni, Fabio
Piazza, Rocco
CANCERS, 2023, 15 (12)
[39] Myelodysplastic syndromes/neoplasms: recent classification system based on World Health Organization Classification of Tumors - International Agency for Research on Cancer for Hematopoietic and Lymphoid Tissues
Gupta, Geetanjali
Singh, Reecha
Kotasthane, Dhananjay S.
Kotasthane, Vaishali D.
JOURNAL OF BLOOD MEDICINE, 2010, 1 : 171 - 182
[40] MDS CLEARPATH: AWEB-BASED EDUCATIONAL ALGORITHM FOR THE DIAGNOSIS AND MANAGEMENT OF PATIENTS WITH MYELODYSPLASTIC SYNDROMES FROM THE CANADIAN CONSORTIUM ON MDS (CCMDS); 2023 UPDATE
Leitch, H.
Leber, B.
Olney, H.
Shamy, A.
LEUKEMIA RESEARCH, 2023, 128

← 1 2 3 4 5 →